Related Experiment Videos
A phase II study of ifosfamide in paediatric solid tumours
1Department of Haematology, Hospital for Sick Children, London, U.K.
Cancer Chemotherapy and Pharmacology
|January 1, 1989
Summary
Ifosfamide chemotherapy shows promise for pediatric cancers. This study found some complete and partial responses in children with recurrent tumors, with manageable side effects.
Area of Science:
- Pediatric Oncology
- Medical Chemotherapy
- Cancer Research
Background:
- Recurrent or unresponsive pediatric tumors present significant treatment challenges.
- Previous therapies, including cyclophosphamide, were often ineffective in these cases.
Purpose of the Study:
- To evaluate the efficacy and tolerability of ifosfamide in children with refractory or recurrent solid tumors.
- To assess response rates and adverse events associated with ifosfamide treatment.
Main Methods:
- Twenty children with various recurrent/unresponsive tumors received ifosfamide (5 g/m2) as a 24-hour infusion with mesna.
- Treatment courses ranged from 1 to 13 (median 3) over 2-3 week intervals.
- Sixteen patients had prior cyclophosphamide exposure.
Main Results:
- Complete clinical responses (CRs) were observed in 3 patients (Wilms' tumor, Ewing's sarcoma) lasting 5-9 months.
- Partial responses (PRs) occurred in 3 patients, with mixed/stable disease in 4, and progressive disease in 10.
- Treatment was generally well-tolerated; notable adverse events included transient neurological symptoms (2) and hypertension (1).
Conclusions:
- Ifosfamide demonstrates activity in a subset of pediatric patients with recurrent or unresponsive solid tumors.
- The regimen was associated with manageable toxicity, including lack of severe myelosuppression or cystitis.
- Further investigation into ifosfamide's role in pediatric oncology is warranted.